Jan 14, 2021 / 04:40PM GMT
Michael Klem -
Good morning, and good afternoon, everybody. Thank you all for joining. My name is Michael Klem. I'm a member of JPMorgan's health care investment banking team here. It's my pleasure to introduce Sean McCarthy, the CEO of CytomX Therapeutics. (Operator Instructions) We also have Amy and Carlos here for Q&A after.
But without further ado, I'll turn it over to you, Sean. Thanks.
Sean A. McCarthy - CytomX Therapeutics, Inc. - Chairman, CEO & President
Great. Thank you very much, Michael, and it's a pleasure to be here today. Thanks to the organizers for the opportunity to present an update on our company. It's a real pleasure to provide an overview of our recent progress on our conditionally activated antibody therapeutic programs for the treatment of cancer and our plans for 2021 and beyond.
If we could advance -- if I could draw your attention to Slide 3. Before I begin, let me remind you that I will be making certain forward-looking statements during this presentation. Please refer to our regulatory filings with the SEC that
CytomX Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers